Endometrial cancer: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• TP53 8
• PD-1 17
• HER2 13
• PTEN 3
• PI3K 7
• PD-L1 6
• mTOR 2
• AKT 2
• CTNNB1 1
• PIK3CA 6
• ARID1A 3
• BRCA1 2
• KRAS 5
• PARP 3
• VEGF 2
• CDK4/6 3
• ERK 0
• GLP-1 3
• STAT3 0
• TROP2 3
• BRCA2 1
• CTLA-4 2
• MAPK 0
• ESR1 0
• AR 0
• ATM 1
• AMPK 1
• AXL 2
• B7-H3 2
• COX-2 0
• FGFR 0
• IGF1R 0
• TIGIT 1
• BCL-2 0
• FTO 0
• GPX4 0
• HDAC 0
• HER3 1
• PALB2 1
• RAS 1
• BRAF 0
• EGFR 2
• EZH2 0
• JAK 0
• JNK 0
• KEAP1 1
• LAG-3 0
• MDM2 0
• MET 0
• MMP-9 0
• NLRP3 0
• PRAME 1
• PSMA 1
• SGLT2 1
• STING 0
• STK11 1
• APOE 0
• CD20 0
• CD47 0
• CDKN2A 0

12 of 12+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Continuous Estrogen Monitoring Patch (EstroPatch)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution €321,301· until May 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Dencatistat, a first-in-class, tumour-agnostic, orally available CTPS1 inhibitor to treat gynaecologic tumours (STP938)

  Step Pharma· Paris, France· EU contribution €2,499,991· until Aug 2027

  The disease is named only in the funder's project summary, not in the title.

2 of 2 running projects, newest first. Listed amounts together: €2.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

  NCT05538897· National Cancer Institute (NCI)· Source

• Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

  NCT01226316· AstraZeneca· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Organoids 3
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 5
• Gene Expression Profiling 37
• Sequence Analysis, RNA 1
• Exome Sequencing 6
• Proteomics 17
• Metabolomics 7
• Mass Spectrometry 1
• Flow Cytometry 1
• Immunohistochemistry 85
• Liquid Biopsy 4
• Circulating Tumor DNA 9
• Xenograft Model Antitumor Assays 38
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 36
• Machine Learning 35
• Deep Learning 18
• Cohort Studies 82
• Genome-Wide Association Study 11

• Deep learning reconstruction-applied PROPELLER diffusion-weighted imaging in uterine malignancies: a comparison study with MUSE.

  Jpn J Radiol, Jul 2026

• PhosSight: A Unified Deep Learning Framework Boosting and Accelerating Phosphoproteome Identification to Enable Biological Discoveries.

  Adv Sci (Weinh), May 2026

• Radiomics-Guided Automatic Delineation for Clinical Target Volume of Endometrial Cancer: Limited Sample Multicenter Study.

  Int J Radiat Oncol Biol Phys, Apr 2026

• Deep learning-based auto-contouring for organs at risk in three-dimensional image-guided brachytherapy for cervical cancer and endometrial cancer.

  J Appl Clin Med Phys, Apr 2026

• CRESCENT: a deep learning framework with multi-scale attention for detecting recurrent copy number alterations.

  Brief Bioinform, Mar 2026

• Deep learning prediction model based on multi-modal transvaginal ultrasound scan images for endometrial cancer.

  Cancer Imaging, Feb 2026

• Preoperative identification of deep myometrial invasion in endometrial cancer: a multicenter MRI study with a vision foundation model-enhanced multimodal deep learning framework.

  Eur J Obstet Gynecol Reprod Biol, Feb 2026

• MRI-based deep learning and radiomics for preoperative prediction of P53abn endometrial cancer: A multicenter study.

  Eur J Radiol, Feb 2026

• Discerning clinical target volume of endometrial cancer via a lightweight multi-phase delineation framework.

  Radiat Oncol, Feb 2026

• AI-driven peptide discovery for endometrial cancer: deep generative modeling and molecular simulation in the big data era.

  J Comput Aided Mol Des, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.